SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities

Table 4 Altered expression (Tumor/Non-tumor) of SWI/SNF members in hematological malignancies

SWI/SNF subunit	Tumor type	Expression (T/N)	Mechanism(s)	Reference
ARID1A	AML	Down	Unknown	[89]
ARID1B	CLL	Down	miRNA regulation	[220]
BCL7A	MM	Down	5’UTR mutations	[123]
BCL7A	CTCL	Down	Hypermethylation	[221]
BCL11A	CLL, NHL, HL, ALL, AML, CML, NKTL	Up	Chromosomal translocation, amplification	[93, 96, 222,223,224,225,226]
BCL11B	ALAL	Up	Chromosomal translocation, enhancer amplification	[99]
SMARCA4	Leukemia & lymphoma cell lines	Down	miRNA regulation	[227, 228]
SMARCB1	AML	Down	Hypermethylation	[92]
SMARCB1	CTCL (SS)	Down	Unknown	[229]

ALAL acute leukemia of ambiguous lineage, ALL acute lymphoid leukemia, AML acute myeloid leukemia, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, CTCL cutaneous T-cell lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, NHL non-Hodgkin lymphoma, NKTL NK/T-cell lymphoma, SS Sézary syndrome

ISSN: 1476-4598